8-K
filed March 27, 2023, 7:59 PM ET
CIK 0001708493
other material
confidence high
sentiment neutral
materiality 0.75
Harpoon raises $25M via preferred equity, posts Q4 2022 net loss of $18.4M
Harpoon Therapeutics, Inc.
- Closed $25M private placement of 8% Series A redeemable preferred stock and warrants ($0.9789 strike, 8-yr).
- Q4 2022 net loss $18.4M; full year 2022 net loss $67.7M (vs $116.7M prior year).
- Q4 revenue $4.1M; full year revenue $31.9M (vs $23.7M prior year).
- Cash, equivalents and marketable securities $53.1M at Dec 31, 2022; cash runway into H2 2024.
- HPN217 (BCMA) Phase 1 dose exploration to complete H1 2023; data presentation expected H2 2023.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Harpoon Therapeutics, Inc. reported the year ended December 31, 2022 results: revenue $31.9 million.
- Period
- the year ended December 31, 2022
- Revenue
- $31.9 million
- Result
- reported results
Exact text from the filing
For the year ended December 31, 2022, revenue was $31.9 million, compared to $23.7 million for the year ended December 31, 2022.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Harpoon Therapeutics, Inc. reported the quarter ended December 31, 2022 results: revenue $4.1 million.
- Period
- the quarter ended December 31, 2022
- Revenue
- $4.1 million
- Result
- reported results
Exact text from the filing
Revenue for the quarter ended December 31, 2022 was $4.1 million, compared to $4.3 million for the quarter ended December 30, 2021.
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Harpoon Therapeutics, Inc.: Filed Certificate of Designation creating 25,000 shares of 8.000% Series A Redeemable Preferred Stock (effective 2023-03-23).
- Change
- charter amendment
- Effective
- 2023-03-23
Exact text from the filing
On March 23, 2023, in connection with the Closing, the Company filed a Certificate of Designation of Preferences, Rights and Limitations (the “Certificate of Designation”) with the Secretary of State of the State of Delaware designating 25,000 shares out of the authorized but unissued shares of its preferred stock as Series A Preferred Stock.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 1.0
Harpoon Therapeutics, Inc. entered into Securities Purchase Agreement with the Purchasers valued at $25.0 million (effective 2023-03-22).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- the Purchasers
- Value
- $25.0 million
- Effective
- 2023-03-22
Exact text from the filing
On March 22, 2023, Harpoon Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), pursuant to which the Company agreed to sell and issue shares of the Company’s 8.000% Series A redeemable preferred stock, par value $0.0001 per share (the “Series A Preferred Stock”), and warrants (the “Warrants”) to purchase shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), in a private placement transaction (the “Private Placement”).
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.